114 related articles for article (PubMed ID: 7511149)
1. Serum TPS versus TPA in Egyptian bladder cancer patients.
Halim AB; el-Ahmady O; Hamza S; Aboul-Ela M; Oehr P
Int J Biol Markers; 1993; 8(4):221-6. PubMed ID: 7511149
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
Mady EA
Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of BEKI TPS radioassay kit as a one-step immunoradiometric assay utilizes monoclonal and polyclonal antibodies specific for serum tissue polypeptide antigen].
Hamase A; Kawanaka M; Kitani H; Fukuchi M
Kaku Igaku; 1994 Aug; 31(8):995-1003. PubMed ID: 7933689
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of urinary CEA, ferritin and TPA in Egyptian bladder cancer patients.
Halim AB; el-Ahmady O; Hamza S; Aboul-Ela M; Oehr P
Int J Biol Markers; 1992; 7(4):234-9. PubMed ID: 1491179
[TBL] [Abstract][Full Text] [Related]
5. Tissue polypeptide antigen and tissue polypeptide specific antigen in primary breast cancer. Evaluation in serum and tumour tissue.
Gion M; Mione R; Barioli P; Sartorello P; Capitanio G
Eur J Clin Chem Clin Biochem; 1994 Oct; 32(10):779-87. PubMed ID: 7865616
[TBL] [Abstract][Full Text] [Related]
6. [Serum and tissue quantification of tissue polypeptide antigen (TPA) in transitional cell carcinoma of the bladder].
Moreno Sierra J; Maestro de las Casas ML; Ortega Heredia MD; Blanco Jimenez E; Hermida Gutiérrez J; Resel Estévez L
Arch Esp Urol; 1994 Dec; 47(10):979-84. PubMed ID: 7864679
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B
Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tissue polypeptide antigen serum levels for monitoring disease activity during chemotherapy in patients with transitional carcinoma of the urinary tract.
van der Gaast A; Kirkels WJ; Blijenberg BG; Splinter TA
J Cancer Res Clin Oncol; 1992; 118(8):626-8. PubMed ID: 1517284
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of serum TPS in gynecological malignancies.
Salman T; el-Ahmady O; Sawsan MR; Nahed MH
Int J Biol Markers; 1995; 10(2):81-6. PubMed ID: 7561243
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
13. [Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit].
Sakahara H; Endo K; Torizuka K; Itoh K; Ohuchi N; Inaba N; Miyaji Y; Takayama M; Ishii K; Takagi H; Konishi J; Fukuoka M; Fukuchi M; Ohkawa J; Kagawa S; Kondo S; Shirouzu K; Iguchi H
Gan To Kagaku Ryoho; 1996 May; 23(6):733-43. PubMed ID: 8645025
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer.
Stieber P; Schmeller N; Schambeck C; Hofmann K; Reiter W; Hasholzner U; Fateh-Moghadam A
Anticancer Res; 1996; 16(6B):3793-8. PubMed ID: 9042259
[TBL] [Abstract][Full Text] [Related]
15. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases.
Stieber P; Dienemann H; Hasholzner U; Fabricius PG; Schambeck C; Weinzierl M; Poley S; Samtleben W; Hofmann K; Meier W
Int J Biol Markers; 1994; 9(2):82-8. PubMed ID: 7523546
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of tissue polypeptide antigen in the follow-up of bladder cancer.
Menéndez López V; Galán JA; Fernández-Suárez A; López-Celada S; Alcover J; Filella X
Urology; 2003 Aug; 62(2):243-8. PubMed ID: 12893327
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of squamous-cell carcinoma antigen and tissue polypeptide antigen in the follow-up of patients with vulvar cancer.
Hefler L; Frischmuth K; Heinze G; Sliutz G; Leodolter S; Reinthaller A; Kainz C; Tempfer C
Int J Cancer; 1999 Oct; 83(2):167-70. PubMed ID: 10471522
[TBL] [Abstract][Full Text] [Related]
18. [A basic and clinical evaluation of a new immunoradiometric assay kit for human serum tissue polypeptide antigen (TPA)].
Shimojo K; Watanabe N; Sakai S; Kobayashi M; Ohtake H; Hatori N; Fukasawa K; Tomiyoshi K; Inoue T; Endo K
Kaku Igaku; 1996 Jun; 33(6):655-61. PubMed ID: 8741511
[TBL] [Abstract][Full Text] [Related]
19. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
20. Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen.
Correale M; Arnberg H; Blockx P; Bombardieri E; Castelli M; Encabo G; Gion M; Klapdor R; Martin M; Nilsson S
Int J Biol Markers; 1994; 9(4):231-8. PubMed ID: 7836801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
